Preclinical evaluation of 68Ga- and 177Lu-Labeled AP-01 for the targeted treatment of prostate cancer with moderate PSMA expression
In this study, AP-01 was successfully synthesized. <sup>68</sup>Ga-AP-01 and <sup>177</sup>Lu-AP-01 were obtained with high radiochemical purity and stability. High binding affinity and PSMA targeting specificity were identified in vitro and in vivo. With significantly enhanced tumor uptake and retention, <sup>177</sup>Lu-AP-01 has the potential to improve therapeutic efficacy for the treatment of prostate cancer with moderate PSMA expression.
Authors
- Simin He (ORCID: https://orcid.org/0000-0001-9728-6313)
- Shaoli Song (ORCID: https://orcid.org/0000-0003-2544-7522)
- Yi Liu (ORCID: https://orcid.org/0000-0002-3884-6605)
- Xiao Wang (ORCID: https://orcid.org/0000-0002-9999-3334)
- Jianping Zhang (ORCID: https://orcid.org/0009-0000-8763-7407)
- Xiaoping Xu (ORCID: https://orcid.org/0000-0001-9656-6233)
- Xiaoyu Pan
- Xuan Huang (ORCID: https://orcid.org/0000-0002-6635-8297)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Xiamen University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- United Imaging Healthcare (China) (CN)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1007/s00259-025-07704-2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China